News & Videos - CLEARSIDE BIOMEDICAL INC.

Thinking about buying stock in Macy's, Immunic, LexinFintech, Provention Bio, or Clearside Biomedical? PR Newswire NEW YORK, Nov. 17, 2022 NEW YORK , Nov. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, IMUX, LX, PRVB, and CLSD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. M:...

Thinking about buying stock in Digital Turbine, Purple Innovation, Clearside Biomedical, Rivian Automotive, or ZipRecruiter? PR Newswire NEW YORK, Nov. 10, 2022 NEW YORK , Nov. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APPS, PRPL, CLSD, RIVN, and ZIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. APPS:...

Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners? PR Newswire NEW YORK, March 28, 2022 NEW YORK , March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ORIC:...

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis PR Newswire LAVAL, QC and ALPHARETTA, Ga., March 28, 2022 XIPERE ® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga. , March 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch...

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis PR Newswire LAVAL, QC and ALPHARETTA, Ga., Oct. 25, 2021 XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid LAVAL, QC and...

Thinking about buying stock in Clearside Biomedical, Uxin, Petco Health and Wellness, Ashford Hospitality Trust, or Uber? PR Newswire NEW YORK, June 15, 2021 NEW YORK , June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, UXIN, WOOF, AHT, and UBER. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CLSD:...

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) PR Newswire LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga. , June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a...

...

Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology PR Newswire LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 LAVAL, Quebec and ALPHARETTA, Ga. , Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...

...

...

...

...

...

...

...

...

Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis PR Newswire LAVAL, Quebec and ALPHARETTA, Ga., Oct. 23, 2019 NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020 LAVAL, Quebec and ALPHARETTA, Ga. , Oct. 23, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye...

...

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 - REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside's proprietary, in-office SCS Microinjector™ platform targeting suprachoroidal space delivery - Recent publication in The Journal of Clinical Investigation highlights the potential of suprachoroidal space delivery for RGX-314 in preclinical studies - In-office delivery of...